{"id":"NCT00282464","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","briefTitle":"A Six-week Flexible Dose Study Evaluating the Efficacy and Safety of Geodon in Patients With Bipolar I Depression.","officialTitle":"A Six-Week, Double-Blind, Multicenter, Placebo-Controlled Study Evaluating the Efficacy and Safety of Flexible Doses of Oral Ziprasidone in Outpatients With Bipolar I Depression","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-02","primaryCompletion":"2008-03","completion":"2008-03","firstPosted":"2006-01-26","resultsPosted":"2009-06-02","lastUpdate":"2021-03-29"},"enrollment":392,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Bipolar Disorder"],"interventions":[{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Geodon (Ziprasidone)","otherNames":[]}],"arms":[{"label":"Ziprasidone 20 and 60mg","type":"ACTIVE_COMPARATOR"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This is a 6-week trial that evaluates the efficacy and safety of Geodon (ziprasidone) in outpatient subjects ages 18 and older with Bipolar Disorder type I, depressed. Subjects are required to undergo a washout period of at least 7 days of any prior med.","primaryOutcome":{"measure":"Change in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score","timeFrame":"Baseline to Week 6","effectByArm":[{"arm":"Ziprasidone 20-80mg Bid","deltaMin":-7.23,"sd":0.79},{"arm":"Placebo","deltaMin":-5.02,"sd":0.71}],"pValues":[{"comp":"OG000 vs OG001","p":"0.002"},{"comp":"OG000 vs OG001","p":"0.019"},{"comp":"OG000 vs OG001","p":"0.038"},{"comp":"OG000 vs OG001","p":"0.069"},{"comp":"OG000 vs OG001","p":"0.053"},{"comp":"OG000 vs OG001","p":"0.154"},{"comp":"OG000 vs OG001","p":"0.007"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":2},"locations":{"siteCount":43,"countries":["United States"]},"refs":{"pmids":["23609405"],"seeAlso":["https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A1281139&StudyName=A%20six-week%20flexible%20dose%20study%20evaluating%20the%20efficacy%20and%20safety%20of%20Geodon%20in%20patients%20with%20bipolar%20I%20depression."]},"adverseEventsSummary":{"seriousAny":{"events":3},"commonTop":["Headache","Nausea","Somnolence","Sedation","Diarrhoea"]}}